Loading...
Radi by sme, aby ste sa stali súčasťou našej komunity. Pripojte sa k nášmu Discordu pre spojenie s nami a ostatnými členmi!
- Ticker
- SKIKON.CO
- Price
- 825.90
- Stock movement down
- -9.50 (-1.09%)
- Company name
- SKAGEN Kon-Tiki A
- Exchange
- (CO ,
- Currency
- DKK )
- Trhová kapitalizácia
- -
- Hodnota ent
- -
- Cena/Predaje
- -
- Cena/Účtovná hodnota
- -
- Výnos dividend
- -
- Rast dividend
- -
- Roky rastu
- -
- Výplata FCF
- -
- Koncové P/E
- -
- Vyprojektované P/E
- -
- PEG
- -
- Rast EPS
- -
- 1 ročná návratnosť
- 19.58%
- 3 ročná návratnosť
- -1.52%
- 5 ročná návratnosť
- 9.62%
- 10 ročná návratnosť
- 3.84%
Naposledy aktualizované: 2025-09-05
DIVIDENDY
SKIKON.CO nevypláca dividendy alebo neboli prijaté žiadne údaje
VALUÁCIE
Pomery valuácie
Loading...
Údaje o pomeroch valuácie
| Koncové P/E | - |
| Cena k OCF | - |
| Cena k FCF | - |
| Cena k EBITDA | - |
| EV k EBITDA | - |
Ocenenie (predaj/účtovná hodnota)
Loading...
Údaje o valuácii (predaj/účtovná hodnota).
| Cena k Predajom | - |
| Cena k účtovnej hodnote | - |
| EV k Predajom | - |
FINANCIE
INFORMÁCIE O AKCIÁCH
Akciové grafy
Loading...
Údaje o cene akcií
| Otvoriť | 862.50 |
| Denné maximum | 862.50 |
| Denné minimum | 862.50 |
| Denný objem | 0K |
| Historické maximum | 1070.92 |
| 1 ročný odhad analytikov | - |
| Beta | - |
| EPS (TTM) | - |
| Dividenda na akciu | - |
| Dátum ex-div | - |
| Ďalší dátum zárobkov | - |
Potenciál poklesu ceny
Loading...
Údaje o potenciáli poklesu ceny
| SKIKON.CO | S&P500 | |
| Aktuálny pokles ceny proti historickému maximu | -19.46% | -1.06% |
| Najvyšší pokles ceny | -57.82% | -56.47% |
| Dátum najvyššieho poklesu | 27 Oct 2008 | 9 Mar 2009 |
| Priemerný pokles z maxima | -14.05% | -10.99% |
| Priemerný čas k novému maximumu | 26 days | 12 days |
| Maximálny čas k novému maximumu | 654 days | 1805 days |
PODROBNOSTI O SPOLOČNOSTI
Trhová kapitalizácia
-
Kategória trhovej kapitalizácie
Small-cap
Popis
SKAGEN - Kon-Tiki fund is an open-ended equity mutual fund launched and managed by Skagen AS. The fund invests in public equity markets of emerging countries across the globe. It seeks to invest in stocks of companies operating across diversified sectors. The fund invests in stocks of companies across diversified market capitalizations. It invests in value stocks of companies. It benchmarks the performance of its portfolio against the MSCI Emerging Markets Index. SKAGEN - Kon-Tiki fund was formed on April 5, 2002 and is domiciled in Norway.
Zamestnanci
0
Vzťahy s investormi
-
SEC podania
CEO
Krajina
Denmark
Mesto
Typ akcie
-
CCC status
-
Dividendová frekvencia
-
PODUJATIA A PREZENTÁCIE
UdalostiPrezentácie
Loading...
POROZUMIEŤ PODNIKU
Loading...
NOVINKY O SPOLOČNOSTI
Všetky novinkyTlačové správy
Lysaker, 27 October 2025 This is a re-submission of the announcement posted at 14:46, with reference to the correct fund (SKAGEN Focus A) at the bottom of this text. With reference to Nasdaq Copenhage...
27. októbra 2025
Lysaker, 27 October 2025 With reference to Nasdaq Copenhagen's rules for issuers of UCITS units, we hereby notify that incorrect intrinsic values were reported on 24 October for SKAGEN Focus A as deta...
27. októbra 2025
The cider brand has added a high-contrast NaviLens QR code to its cans.
9. septembra 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
9. septembra 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
9. septembra 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
9. septembra 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
9. septembra 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
9. septembra 2025
Lysaker, 10 July 2025 The semi annual report for securities funds managed by Storebrand Asset Management AS was approved by the Board of Directors today, and has now been released (only in Norwegian l...
10. júla 2025
Lysaker, 5 June 2025 The prospectuses have been updated as the document structure between SKAGEN funds and Storebrand funds have been aligned with the latter. There are no material changes, but all pr...
5. júna 2025
Ďalšia strana